Heidi W Thermenos1, Richard J Juelich2, Samantha R DiChiara3, Raquelle I Mesholam-Gately4, Kristen A Woodberry4, Joanne Wojcik4, Nikos Makris5, Matcheri S Keshavan4, Susan Whitfield-Gabrieli6, Tsung-Ung W Woo7, Tracey L Petryshen3, Jill M Goldstein8, Martha E Shenton9, Robert W McCarley9, Larry J Seidman10. 1. Harvard Medical School, Boston, MA, USA; Massachusetts Mental Health Center Division of Public Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. Electronic address: hthermen@bidmc.harvard.edu. 2. Harvard Medical School, Boston, MA, USA; Department of Psychiatry, McLean Hospital, Belmont, MA, USA. 3. Harvard Medical School, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. 4. Harvard Medical School, Boston, MA, USA; Massachusetts Mental Health Center Division of Public Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, USA. 5. Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA. 6. McGovern Institute for Brain Research, Poitras Center for Affective Disorders Research, Massachusetts Institute of Technology, Cambridge, MA, USA. 7. Harvard Medical School, Boston, MA, USA; Massachusetts Mental Health Center Division of Public Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, USA; Laboratory of Cellular Neuropathology, McLean Hospital, Belmont, MA, USA. 8. Harvard Medical School, Boston, MA, USA; Department of Medicine, Division of Women's Health, Connor's Center for Women's Health & Gender Biology, Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, USA. 9. Harvard Medical School, Boston, MA, USA; Psychiatry Neuroimaging Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; VA Boston Healthcare System, Brockton, MA, USA. 10. Harvard Medical School, Boston, MA, USA; Massachusetts Mental Health Center Division of Public Psychiatry, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Deficits in working memory (WM) are a core feature of schizophrenia (SZ) and other psychotic disorders. We examined brain activity during WM in persons at clinical high risk (CHR) for psychosis. METHODS: Thirty-seven CHR and 34 healthy control participants underwent functional MRI (fMRI) on a 3.0T scanner while performing an N-back WM task. The sample included a sub-sample of CHR participants who had no lifetime history of treatment with psychotropic medications (n=11). Data were analyzed using SPM8 (2-back>0-back contrast). Pearson correlations between brain activity, symptoms, and WM performance were examined. RESULTS: The total CHR group and medication-naive CHR sub-sample were comparable to controls in most demographic features and in N-back WM performance, but had significantly lower IQ. Relative to controls, medication-naïve CHR showed hyperactivity in the left parahippocampus (PHP) and the left caudate during performance of the N-back WM task. Relative to medication-exposed CHR, medication naïve CHR exhibited hyperactivity in the left caudate and the right dorsolateral prefrontal cortex (DLPFC). DLPFC activity was significantly negatively correlated with WM performance. PHP, caudate and DLPFC activity correlated strongly with symptoms, but results did not withstand FDR-correction for multiple comparisons. When all CHR participants were combined (regardless of medication status), only trend-level PHP hyperactivity was observed in CHR relative to controls. CONCLUSIONS: Medication-naïve CHR exhibit hyperactivity in regions that subserve WM. These regions are implicated in studies of schizophrenia and risk for psychosis. Results emphasize the importance of medication status in the interpretation of task - induced brain activity.
BACKGROUND:Deficits in working memory (WM) are a core feature of schizophrenia (SZ) and other psychotic disorders. We examined brain activity during WM in persons at clinical high risk (CHR) for psychosis. METHODS: Thirty-seven CHR and 34 healthy control participants underwent functional MRI (fMRI) on a 3.0T scanner while performing an N-back WM task. The sample included a sub-sample of CHR participants who had no lifetime history of treatment with psychotropic medications (n=11). Data were analyzed using SPM8 (2-back>0-back contrast). Pearson correlations between brain activity, symptoms, and WM performance were examined. RESULTS: The total CHR group and medication-naive CHR sub-sample were comparable to controls in most demographic features and in N-back WM performance, but had significantly lower IQ. Relative to controls, medication-naïve CHR showed hyperactivity in the left parahippocampus (PHP) and the left caudate during performance of the N-back WM task. Relative to medication-exposed CHR, medication naïve CHR exhibited hyperactivity in the left caudate and the right dorsolateral prefrontal cortex (DLPFC). DLPFC activity was significantly negatively correlated with WM performance. PHP, caudate and DLPFC activity correlated strongly with symptoms, but results did not withstand FDR-correction for multiple comparisons. When all CHR participants were combined (regardless of medication status), only trend-level PHP hyperactivity was observed in CHR relative to controls. CONCLUSIONS: Medication-naïve CHR exhibit hyperactivity in regions that subserve WM. These regions are implicated in studies of schizophrenia and risk for psychosis. Results emphasize the importance of medication status in the interpretation of task - induced brain activity.
Authors: Paul Allen; Marc L Seal; Isabel Valli; Paolo Fusar-Poli; Cinzia Perlini; Fern Day; Stephen J Wood; Steven C Williams; Philip K McGuire Journal: Schizophr Bull Date: 2009-11-23 Impact factor: 9.306
Authors: Paolo Fusar-Poli; Nicolas Crossley; James Woolley; Francesco Carletti; Rocio Perez-Iglesias; Matthew Broome; Louise Johns; Paul Tabraham; Elvira Bramon; Philip McGuire Journal: Neuroimage Date: 2010-12-01 Impact factor: 6.556
Authors: H W Thermenos; M S Keshavan; R J Juelich; E Molokotos; S Whitfield-Gabrieli; B K Brent; N Makris; L J Seidman Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2013-10 Impact factor: 3.568
Authors: M R Broome; F Day; I Valli; L Valmaggia; L C Johns; O Howes; P Garety; P K McGuire Journal: Eur Psychiatry Date: 2010-10-08 Impact factor: 5.361
Authors: P Fusar-Poli; R Smieskova; M J Kempton; B C Ho; N C Andreasen; S Borgwardt Journal: Neurosci Biobehav Rev Date: 2013-06-14 Impact factor: 8.989
Authors: Rick P F Wolthusen; Garth Coombs; Emily A Boeke; Stefan Ehrlich; Stephanie N DeCross; Shahin Nasr; Daphne J Holt Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2017-07-13
Authors: Guusje Collin; Clemens C C Bauer; Sheeba Arnold Anteraper; John D E Gabrieli; Elena Molokotos; Raquelle Mesholam-Gately; Heidi W Thermenos; Larry J Seidman; Matcheri S Keshavan; Martha E Shenton; Susan Whitfield-Gabrieli Journal: Front Psychiatry Date: 2021-02-09 Impact factor: 4.157
Authors: Jens Gisselgård; Alexander V Lebedev; Kathinka Dæhli Kurz; Inge Joa; Jan Olav Johannessen; Kolbjørn Brønnick Journal: PLoS One Date: 2018-05-09 Impact factor: 3.240